| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Medical Microbiology and Immunology, University of Göteborg, Göteborg, Sweden;
Department of Molecular Biology, Astra Hässle AB, Mölndal, Sweden; and
Institute of Pathology, Case Western Reserve University, Cleveland, OH
The ADP-ribosylating enterotoxins, cholera toxin (CT) and Escherichia coli heat-labile toxin, are among the most powerful immunogens and adjuvants yet described. An innate problem, however, is their strong toxic effects, largely due to their promiscuous binding to all nucleated cells via their B subunits. Notwithstanding this, their exceptional immunomodulating ability is attracting increasing attention for use in systemic and mucosal vaccines. Whereas others have separated adjuvanticity from toxicity by disrupting the enzymatic activity of the A1 subunit by site-directed mutagenesis, we have constructed a nontoxic molecule that combines the full enzymatic activity of the A1 subunit with a B cell targeting moiety in a gene fusion protein, the CTA1-DD adjuvant. Despite its more selective binding properties, we found comparable adjuvant effects of the novel CTA1-DD adjuvant to that of CT. Here we unequivocally demonstrate, using a panel of mutant CTA1-DD molecules, that the immunomodulating ability of CTA1-DD is dependent on both an intact enzymatic activity and the Ig-binding ability of the DD dimer. Both agents, CT and CTA1-DD, ADP-ribosylate intact B cells. However, contrary to CT, no increase in intracellular cyclic AMP in the targeted cells was detected, suggesting that cyclic AMP may not be important for adjuvanticity. Most remarkably, CTA1-DD achieves similar immunomodulating effects to CT using a ganglioside-GM1 receptor-independent pathway for internalization.
This article has been cited by other articles:
|
|
 |
|
  D. R. M. Negri, D. Pinto, S. Vendetti, M. Patrizio, M. Sanchez, A. Riccomi, P. Ruggiero, G. Del Giudice, and M. T. De Magistris Cholera Toxin and Escherichia coli Heat-Labile Enterotoxin, but Not Their Nontoxic Counterparts, Improve the Antigen-Presenting Cell Function of Human B Lymphocytes Infect. Immun., May 1, 2009; 77(5): 1924 - 1935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Andersen, J. Dietrich, E. M. Agger, N. Y. Lycke, K. Lovgren, and P. Andersen The Combined CTA1-DD/ISCOMs Vector Is an Effective Intranasal Adjuvant for Boosting Prior Mycobacterium bovis BCG Immunity to Mycobacterium tuberculosis Infect. Immun., January 1, 2007; 75(1): 408 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Helgeby, N. C. Robson, A. M. Donachie, H. Beackock-Sharp, K. Lovgren, K. Schon, A. Mowat, and N. Y. Lycke The Combined CTA1-DD/ISCOM Adjuvant Vector Promotes Priming of Mucosal and Systemic Immunity to Incorporated Antigens by Specific Targeting of B Cells J. Immunol., March 15, 2006; 176(6): 3697 - 3706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Duverger, R. J. Jackson, F. W. van Ginkel, R. Fischer, A. Tafaro, S. H. Leppla, K. Fujihashi, H. Kiyono, J. R. McGhee, and P. N. Boyaka Bacillus anthracis Edema Toxin Acts as an Adjuvant for Mucosal Immune Responses to Nasally Administered Vaccine Antigens J. Immunol., February 1, 2006; 176(3): 1776 - 1783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Hajishengallis, S. Arce, C.M. Gockel, T.D. Connell, and M.W. Russell Immunomodulation with Enterotoxins for the Generation of Secretory Immunity or Tolerance: Applications for Oral Infections Journal of Dental Research, December 1, 2005; 84(12): 1104 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Eriksson, K. M. Schon, and N. Y. Lycke The Cholera Toxin-Derived CTA1-DD Vaccine Adjuvant Administered Intranasally Does Not Cause Inflammation or Accumulate in the Nervous Tissues J. Immunol., September 1, 2004; 173(5): 3310 - 3319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. I. Mowat, A. M. Donachie, S. Jagewall, K. Schon, B. Lowenadler, K. Dalsgaard, P. Kaastrup, and N. Lycke CTA1-DD-Immune Stimulating Complexes: a Novel, Rationally Designed Combined Mucosal Vaccine Adjuvant Effective with Nanogram Doses of Antigen J. Immunol., September 15, 2001; 167(6): 3398 - 3405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Boirivant, I. J. Fuss, L. Ferroni, M. De Pascale, and W. Strober Oral Administration of Recombinant Cholera Toxin Subunit B Inhibits IL-12-Mediated Murine Experimental (Trinitrobenzene Sulfonic Acid) Colitis J. Immunol., March 1, 2001; 166(5): 3522 - 3532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Agren, E. Sverremark, L. Ekman, K. Schon, B. Lowenadler, C. Fernandez, and N. Lycke The ADP-Ribosylating CTA1-DD Adjuvant Enhances T Cell-Dependent and Independent Responses by Direct Action on B Cells Involving Anti-Apoptotic Bcl-2- and Germinal Center-Promoting Effects J. Immunol., June 15, 2000; 164(12): 6276 - 6286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Weltzin, B. Guy, W. D. Thomas Jr., P. J. Giannasca, and T. P. Monath Parenteral Adjuvant Activities of Escherichia coli Heat-Labile Toxin and Its B Subunit for Immunization of Mice against Gastric Helicobacter pylori Infection Infect. Immun., May 1, 2000; 68(5): 2775 - 2782. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
